Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries

[1]  R. Sullivan,et al.  Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. , 2018, Journal of the American College of Cardiology.

[2]  G. Varricchi,et al.  Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors: It Is Now Time for Cardio-Immuno-Oncology. , 2018, Journal of the American College of Cardiology.

[3]  J. Grob,et al.  Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. , 2017, Circulation.

[4]  D. Sueta,et al.  Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody. , 2017 .

[5]  J. Kuiper,et al.  Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis , 2017, British journal of pharmacology.

[6]  P. Tornero,et al.  First case of allergy to nivolumab. , 2017, The journal of allergy and clinical immunology. In practice.

[7]  S. Agrawal,et al.  Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors , 2017, Journal of clinical pharmacology.

[8]  Douglas B. Johnson,et al.  Cardiovascular Toxicities Associated with Cancer Immunotherapies , 2017, Current Cardiology Reports.

[9]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[10]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[11]  Mary E Reid,et al.  The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Hussein Tawbi,et al.  Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy , 2016, Journal of Immunotherapy for Cancer.

[13]  J. Utikal,et al.  Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. , 2016, European journal of cancer.

[14]  Keunchil Park,et al.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.

[15]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[16]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[18]  F. Hodi,et al.  Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. , 2015, The New England journal of medicine.

[19]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[20]  R. Memmott,et al.  Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer , 2014, Oncotarget.

[21]  V. Appay,et al.  [Influence of PD-1 on the immunological synapse: a facet of immune regulation ?]. , 2013, Medecine sciences : M/S.

[22]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[23]  J. Vansteenkiste,et al.  Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  A. Sharpe,et al.  PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis , 2012, The Journal of Immunology.

[25]  Drew M Pardoll,et al.  Cancer immunotherapy comes of age. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Loise M. Francisco,et al.  The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.

[27]  Yoshimasa Tanaka,et al.  Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice , 2003, Nature Medicine.

[28]  G. Freeman,et al.  The B7–CD28 superfamily , 2002, Nature Reviews Immunology.

[29]  T. Okazaki,et al.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. , 2001, Science.

[30]  A. Takeshita,et al.  Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. , 1996, The Journal of clinical investigation.

[31]  J. Koyama,et al.  Intravascular ultrasound detection of atherosclerosis at the site of focal vasospasm in angiographically normal or minimally narrowed coronary segments. , 1994, Journal of the American College of Cardiology.

[32]  D. Greenblatt,et al.  A method for estimating the probability of adverse drug reactions , 1981, Clinical pharmacology and therapeutics.